<DOC>
	<DOC>NCT01580228</DOC>
	<brief_summary>This study is being conducted to demonstrate the superiority in progression-free survival (PFS) of dinaciclib compared to ofatumumab in chronic lymphocytic leukemia (CLL) participants with del 17p or in the overall population who are refractory to either fludarabine treatment or chemoimmunotherapy.</brief_summary>
	<brief_title>A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)</brief_title>
	<detailed_description>Dinaciclib is a cyclin-dependent kinase (CDK) inhibitor, specific for CDK 1, 2, 5 and 9.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Aged 18 years or older Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) Fludarabine or chemoimmunotherapy refractory disease defined as: failing to respond to or relapsed within 6 months of completing fludarabine or another purine analog alone or in combination regimens, or failing to respond to chemoimmunotherapy or relapsed within 24 months of completing therapy with a combination of chemotherapy plus an antiCD20 monoclonal antibody Eastern Cooperative Oncology Group (ECOG) Performance status 0, 1, or 2 Adequate organ function and laboratory parameters Women of childbearing potential who are not currently sexually active must agree to use a medically accepted method of contraception should they become sexually active while participating in the study Symptomatic brain metastases or primary central nervous system malignancy Treatment with a CYP3A4 inhibitor or inducer within 1 week prior to randomization, or any chemotherapy or biologic therapy within 4 weeks prior to randomization Known human immunodeficiency virus (HIV) infection or a known HIVrelated malignancy Participants with with clinically active hepatitis B or C defined as disease that requires therapy Positive test for glucose6 phosphate dehydrogenase (G6PD) deficiency Prior allogeneic bone marrow transplant Presence of Richter's transformation Indeterminate deletion 17p status Previous treatment with ofatumumab, dinaciclib, or other CDK inhibitors Active autoimmune anemia or thrombocytopenia unless stable, which is defined as being responsive to corticosteroids or other standard therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>